Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析

◆英語タイトル:Luye Pharma Group Ltd (2186) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14894
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Luye Pharma Group Ltd (Luye Pharma Group) is a drug company that manufactures, develops, discovers, and commercializes novel formulations, natural drugs, medicinal products, pharmaceutical products, and biotechnology products. The group’s products include paclitaxel liposome, lentinan, sodium glycididazole, arsenious acid, and xuezhikang, among others. It also provides amifostine, oxaliplatin, meloxicam, pioglitazone hydrochloride, reduced glutathione, and selegiline hydrochloride, among others. Luye Pharma Group’s products are used in therapeutic areas including endocrinology, oncology, cardiovascular, orthopedics, gastroenterology, hepatology, gynecology, and central nervous system, among others. The group offers its products through its distributors located across China. Luye Pharma Group is headquartered in Yantai, China.

Luye Pharma Group Ltd Key Recent Developments

Jan 17,2019: AstraZeneca licences Luye Pharma cholesterol drug in China
Sep 20,2018: Luye Pharma Strengthens Its Global CNS Portfolio with Patch Product for the Treatment of Alzheimer’s Soon to be Launched in China
Aug 26,2018: Luye Pharma Group reports interim results for the six months ended 30 June 2018
Aug 03,2018: Luye Pharma: Change of information of director

This comprehensive SWOT profile of Luye Pharma Group Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Luye Pharma Group Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Luye Pharma Group Ltd – Key Information
Luye Pharma Group Ltd – Overview
Luye Pharma Group Ltd – Key Employees
Luye Pharma Group Ltd – Key Employee Biographies
Luye Pharma Group Ltd – Key Operational Heads
Luye Pharma Group Ltd – Major Products and Services
Luye Pharma Group Ltd – History
Luye Pharma Group Ltd – Company Statement
Luye Pharma Group Ltd – Locations And Subsidiaries
Luye Pharma Group Ltd – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Luye Pharma Group Ltd – Business Description
Luye Pharma Group Ltd – Corporate Strategy
Luye Pharma Group Ltd – SWOT Analysis
SWOT Analysis – Overview
Luye Pharma Group Ltd – Strengths
Luye Pharma Group Ltd – Weaknesses
Luye Pharma Group Ltd – Opportunities
Luye Pharma Group Ltd – Threats
Luye Pharma Group Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

Luye Pharma Group Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Luye Pharma Group Ltd, Key Information
Luye Pharma Group Ltd, Key Ratios
Luye Pharma Group Ltd, Share Data
Luye Pharma Group Ltd, Major Products and Services
Luye Pharma Group Ltd, History
Luye Pharma Group Ltd, Key Employees
Luye Pharma Group Ltd, Key Employee Biographies
Luye Pharma Group Ltd, Key Operational Heads
Luye Pharma Group Ltd, Other Locations
Luye Pharma Group Ltd, Subsidiaries
Luye Pharma Group Ltd, Key Manufacturing facilities
Luye Pharma Group Ltd, Key Competitors
Luye Pharma Group Ltd, SWOT Analysis
Luye Pharma Group Ltd, Ratios based on current share price
Luye Pharma Group Ltd, Annual Ratios
Luye Pharma Group Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Luye Pharma Group Ltd, Performance Chart
Luye Pharma Group Ltd, Ratio Charts

★海外企業調査レポート[Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Allinky Biopharma SL:医療機器:M&Aディール及び事業提携情報
    Summary Allinky Biopharma SL (Allinky) is a developer of small molecules for the treatment of cancer and inflammatory diseases. The company offers research and development of basic and clinical sciences and discovery of novel therapies. Its therapeutic agents comprise active site drugs, target prote …
  • iPass Inc.:企業の戦略的SWOT分析
    iPass Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Allergan plc:企業の戦略・SWOT・財務情報
    Allergan plc - Strategy, SWOT and Corporate Finance Report Summary Allergan plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sino Gas & Energy Holdings Ltd (SEH):企業の財務・戦略的SWOT分析
    Summary Sino Gas & Energy Holdings Ltd (Sino Gas), a subsidiary of MIE Holdings Corp, is an oil and gas company that explores and develops unconventional gas assets production sharing contracts. The company holds working interest in the Linxing PSC and the Sanjiaobei PSC projects. It has strategic A …
  • Forward Industries, Inc. (FORD):企業の財務・戦略的SWOT分析
    Forward Industries, Inc. (FORD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Automotive Holdings Group Limited:企業のM&A・事業提携・投資動向
    Automotive Holdings Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Automotive Holdings Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Apoteket AB:企業の戦略的SWOT分析
    Apoteket AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Pharmathen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析
    Summary Pharmathen Pharmaceuticals SA (Pharmathen) is a healthcare products provider that develops and markets generic products. The company’s products include oral antiplatelet agent, bactericidal cephalosporin antibiotic, retinoid, beta1-selective adrenergic receptor blocking agent, and others. It …
  • Hallador Energy Co (HNRG):企業の財務・戦略的SWOT分析
    Hallador Energy Co (HNRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • American Axle & Manufacturing Holdings, Inc.:企業の戦略・SWOT・財務情報
    American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Axle & Manufacturing Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Co.don AG (CNWK):医療機器:M&Aディール及び事業提携情報
    Summary Co.don AG (Co.don) offers tissue engineering solutions in cultivation and growth of autologous tissue cells for the regenerative treatment of articular cartilage defects and spinal disc defects. The company manufactures and markets autologous, cell-based pharmaceutical products for biologica …
  • Fonterra Co-operative Group Ltd:企業のM&A・事業提携・投資動向
    Fonterra Co-operative Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fonterra Co-operative Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Peel Hotels Plc:企業の戦略・SWOT・財務情報
    Peel Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary Peel Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • SANUWAVE Health Inc (SNWV):企業の財務・戦略的SWOT分析
    Summary Sanuwave Health Inc (Sanuwave), formerly Rub Music Enterprises Inc, is a medical device company that develops and commercializes noninvasive biological response activating devices. The company offers products such as dermapace, which is used in the treatment of chronic and acute conditions o …
  • Sprint Bioscience AB (SPRINT):企業の財務・戦略的SWOT分析
    Summary Sprint Bioscience AB (Sprint Bioscience) is a developer of pharmaceutical products in the areas of cancer and metabolism. The company develops STK25, a drug candidate against a new target protein for the treatment of type 2 diabetes; VPS34, a drug candidate for the treatment of various types …
  • Societe Generale S.A.:企業の戦略・SWOT・財務分析
    Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report Summary Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • GeNeuro SA (GNRO):製薬・医療:M&Aディール及び事業提携情報
    Summary GeNeuro SA (GeNeuro) is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develops therap …
  • Mitobridge Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mitobridge Inc (Mitobridge), formerly Mitokyne, Inc. is a drug development company that discovers and develops small molecule therapeutics. The company offers products that enhance the mitochondrial functions. It develops therapies for rare diseases and then expand into more common diseases. …
  • American Greetings Corporation (AM):企業の戦略的SWOT分析
    American Greetings Corporation (AM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Wilbur-Ellis Holdings Inc:企業の戦略的SWOT分析
    Wilbur-Ellis Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆